APP and Alzheimer disease: The Cef treatment, by upregulating GLT-1 expression, suppresses the expression of mGluR2 contributing to the reversal of the recognition memory deficits of APP/PS1 AD mice and the upregulation in the expression of PKA and SNAP-25, at least partly, is involved in the process.